83 FR 51968 - Government-Owned Inventions; Availability for Licensing

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 83, Issue 199 (October 15, 2018)

Page Range		51968-51968
FR Document		2018-22317

The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research and development.

Federal Register, Volume 83 Issue 199 (Monday, October 15, 2018)

[Federal Register Volume 83, Number 199 (Monday, October 15, 2018)]
[Notices]
[Page 51968]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2018-22317]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing to achieve expeditious 
commercialization of results of federally-funded research and 
development.

FOR FURTHER INFORMATION CONTACT: Licensing information may be obtained 
by emailing the indicated licensing contact at the National Heart, 
Lung, and Blood, Office of Technology Transfer and Development Office 
of Technology Transfer, 31 Center Drive Room 4A29, MSC2479, Bethesda, 
MD 20892-2479; telephone: 301-402-5579. A signed Confidential 
Disclosure Agreement may be required to receive any unpublished 
information.

SUPPLEMENTARY INFORMATION: Technology description follows.
    TSLP for treatment of pulmonary methicillin-resistant S. aureus 
(MRSA) infection. Available for licensing and commercial development is 
a patent estate covering methods of promoting the host defense of a 
patient suffering from or at risk of a bacterial infection 
(Methicillin-resistant Staphylococcus aureus (MRSA) infection in 
particular) by administering a thymic stromal lymphopoeitin (TSLP) 
protein or polypeptide. TSLP induces neutrophil mediated killing of 
MRSA bacteria mediated by reactive oxygen species and complement. 
Community-acquired Staphylococcus aureus infections often present as 
serious skin infections in otherwise healthy individuals and have 
become a worldwide epidemic fueled by the emergence of strains with 
antibiotic resistance. The cytokine TSLP is highly expressed in the 
skin and in other barrier surfaces and plays a deleterious role by 
promoting T helper cell type 2 (TH2) responses during allergic 
diseases. The present methodology is based on a finding of non-TH2's 
role for TSLP in enhancing neutrophil killing of MRSA during an in vivo 
skin infection. TSLP also enhances killing of Streptococcus pyogenes, 
another clinically important cause of human skin infections. 
Unexpectedly, TSLP mechanistically mediates antibacterial effects by 
directly engaging the complement C5 system to modulate production of 
reactive oxygen species by neutrophils.
    Potential Commercial Applications:
     MRSA infection.
    Inventors: Warren Leonard, Erin West, Rosanne Spolski (all of 
NHLBI) and Christopher Garcia (Stanford).
    Relevant Publications:
     J Immunol May 1, 2016, 196 (1 Supplement) 60.5;
     Sci Immunol. 2016 Nov 18;1(5).
    Intellectual Property: HHS Reference No. E-034-2016,
    Licensing Contact: Michael Shmilovich, Esq, CLP; 301-435-5019; 
[email protected].

    Dated: September 25, 2018.
Michael A. Shmilovich,
Senior Licensing and Patenting Manager, National Heart, Lung, and Blood 
Institute, Office of Technology Transfer and Development.
[FR Doc. 2018-22317 Filed 10-12-18; 8:45 am]
 BILLING CODE 4140-01-P

51968 Federal Register / Vol. 83, No. 199 / Monday, October 15, 2018 / Notices

DEPARTMENT OF HEALTH AND commercialization of results of Dated: September 25, 2018.
HUMAN SERVICES federally-funded research and Michael A. Shmilovich,
development. Senior Licensing and Patenting Manager,
National Institutes of Health FOR FURTHER INFORMATION CONTACT: National Heart, Lung, and Blood Institute,
Licensing information may be obtained Office of Technology Transfer and
National Human Genome Research Development.
Institute; Notice of Closed Meeting by emailing the indicated licensing
contact at the National Heart, Lung, and [FR Doc. 2018–22317 Filed 10–12–18; 8:45 am]
Pursuant to section 10(d) of the Blood, Office of Technology Transfer BILLING CODE 4140–01–P
Federal Advisory Committee Act, as and Development Office of Technology
amended, notice is hereby given of a Transfer, 31 Center Drive Room 4A29,
meeting of the National Human Genome MSC2479, Bethesda, MD 20892–2479; DEPARTMENT OF HEALTH AND
Research Institute Special Emphasis telephone: 301–402–5579. A signed HUMAN SERVICES
Panel. Confidential Disclosure Agreement may
The meeting will be closed to the be required to receive any unpublished National Institutes of Health
public in accordance with the information.
provisions set forth in sections National Institute of Allergy and
SUPPLEMENTARY INFORMATION:
552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Technology description follows. Infectious Diseases; Notice of Closed
as amended. The grant applications and TSLP for treatment of pulmonary Meeting
the discussions could disclose methicillin-resistant S. aureus (MRSA)
confidential trade secrets or commercial infection. Available for licensing and Pursuant to section 10(d) of the
property such as patentable material, commercial development is a patent Federal Advisory Committee Act, as
and personal information concerning estate covering methods of promoting amended, notice is hereby given of the
individuals associated with the grant the host defense of a patient suffering following meeting.
applications, the disclosure of which from or at risk of a bacterial infection The meeting will be closed to the
would constitute a clearly unwarranted (Methicillin-resistant Staphylococcus public in accordance with the
invasion of personal privacy. aureus (MRSA) infection in particular) provisions set forth in sections
Name of Committee: National Human by administering a thymic stromal 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
Genome Research Institute Special Emphasis lymphopoeitin (TSLP) protein or as amended. The grant applications and
Panel; Charles Lee Application 2 U24 polypeptide. TSLP induces neutrophil the discussions could disclose
HG007479–05. mediated killing of MRSA bacteria confidential trade secrets or commercial
Date: November 9, 2018. mediated by reactive oxygen species property such as patentable material,
Time: 5:00 p.m. to 6:00 p.m. and complement. Community-acquired and personal information concerning
Agenda: To review and evaluate grant Staphylococcus aureus infections often individuals associated with the grant
applications. present as serious skin infections in applications, the disclosure of which
Place: Residence Inn Bethesda Downtown,
7355 Wisconsin Avenue, Room Calvert II,
otherwise healthy individuals and have would constitute a clearly unwarranted
Bethesda, MD 20814 (Telephone Conference become a worldwide epidemic fueled by invasion of personal privacy.
Call). the emergence of strains with antibiotic Name of Committee: National Institute of
Contact Person: Keith McKenney, Ph.D., resistance. The cytokine TSLP is highly Allergy and Infectious Diseases Special
Scientific Review Officer, NHGRI, 5635 expressed in the skin and in other Emphasis Panel Global Infectious Disease
Fishers Lane, Suite 4076, Bethesda, MD barrier surfaces and plays a deleterious Research Administration Development
20814, 301–594–4280, mckenneyk@ role by promoting T helper cell type 2 Award for Low- and Middle-Income Country
mail.nih.gov. (TH2) responses during allergic Institutions (G11).
(Catalogue of Federal Domestic Assistance diseases. The present methodology is Date: November 6, 2018.
Program Nos. 93.172, Human Genome based on a finding of non-TH2’s role for Time: 1:00 p.m. to 3:00 p.m.
Research, National Institutes of Health, HHS) TSLP in enhancing neutrophil killing of Agenda: To review and evaluate grant
Dated: October 5, 2018. MRSA during an in vivo skin infection. applications.
Sylvia L. Neal, TSLP also enhances killing of Place: National Institutes of Health, 5601
Streptococcus pyogenes, another Fishers Lane, Rockville, MD 20892
Program Analyst, Office of Federal Advisory
Committee Policy. clinically important cause of human (Telephone Conference Call).
skin infections. Unexpectedly, TSLP Contact Person: Zhuqing (Charlie) Li,
[FR Doc. 2018–22314 Filed 10–12–18; 8:45 am]
mechanistically mediates antibacterial Ph.D., Scientific Review Officer, Scientific
BILLING CODE 4140–01–P
effects by directly engaging the Review Program, Division of Extramural
complement C5 system to modulate Activities, Room # 3G41B, National Institutes
production of reactive oxygen species of Health/NIAID, 5601 Fishers Lane, MSC
DEPARTMENT OF HEALTH AND
by neutrophils. 9834, Bethesda, MD 20892–9834, (240) 669–
HUMAN SERVICES
Potential Commercial Applications: 5068, zhuqing.li@nih.gov.
National Institutes of Health • MRSA infection. (Catalogue of Federal Domestic Assistance
Inventors: Warren Leonard, Erin West, Program Nos. 93.855, Allergy, Immunology,
Government-Owned Inventions; Rosanne Spolski (all of NHLBI) and and Transplantation Research; 93.856,
Availability for Licensing Christopher Garcia (Stanford). Microbiology and Infectious Diseases
Relevant Publications: Research, National Institutes of Health, HHS)
• J Immunol May 1, 2016, 196 (1
khammond on DSK30JT082PROD with NOTICES

AGENCY: National Institutes of Health,
HHS. Supplement) 60.5; Dated: October 5, 2018.
ACTION: Notice. • Sci Immunol. 2016 Nov 18;1(5).
Natasha M. Copeland,
Intellectual Property: HHS Reference
SUMMARY: The inventions listed below No. E–034–2016, Program Analyst, Office of Federal Advisory
are owned by an agency of the U.S. Licensing Contact: Michael Committee Policy.
Government and are available for Shmilovich, Esq, CLP; 301–435–5019; [FR Doc. 2018–22313 Filed 10–12–18; 8:45 am]
licensing to achieve expeditious shmilovm@mail.nih.gov. BILLING CODE 4140–01–P

VerDate Sep<11>2014 21:34 Oct 12, 2018 Jkt 247001 PO 00000 Frm 00046 Fmt 4703 Sfmt 9990 E:\FR\FM\15OCN1.SGM 15OCN1

Document Created: 2018-10-13 10:01:46
Document Modified: 2018-10-13 10:01:46

Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Notices
Action		Notice.
Contact		Licensing information may be obtained by emailing the indicated licensing contact at the National Heart, Lung, and Blood, Office of Technology Transfer and Development Office of Technology Transfer, 31 Center Drive Room 4A29, MSC2479, Bethesda, MD 20892-2479; telephone: 301-402-5579. A signed Confidential Disclosure Agreement may be required to receive any unpublished information.
FR Citation		83 FR 51968

83 FR 51968 - Government-Owned Inventions; Availability for Licensing

DEPARTMENT OF HEALTH AND HUMAN SERVICESNational Institutes of Health

Federal Register Volume 83, Issue 199 (October 15, 2018)

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health